4th NovAliX Conference

Biophysics in Drug Discovery 2017

Developing the Synergy between Biophysics and Medicinal Chemistry to Deliver Better Drugs

 Strasbourg, France    June 6-9, 2017

Keynote Speakers

Cutting-Edge Mass Spectrometry Methods for the Multi-Level Structural Characterization of mAbs and ADCs (KL03)

Dr Alain BECK
Dr Alain BECK
PIERRE FABRE, St Julien-en-Genevois, France
Read more

Allosteric Mechanisms of Signal Transduction Investigated with Pentameric Ligand Gated Ion Channels: Consequences for Drug Design (KL01)

Prof. Jean-Pierre CHANGEUX
Prof. Jean-Pierre CHANGEUX
COLLÈGE DE FRANCE & INSTITUT PASTEUR, Paris, France
Read more

FBLD and Biophysics: Better Together (KL02)

Dr Dan ERLANSON
Dr Dan ERLANSON
CARMOT THERAPEUTICS, South San Francisco, United States
Read more

Session 1: Biophysical Techniques for the Study of Integral Membrane Proteins

Method for Rapid Optimization of Recombinant GPCR Protein Expression and Stability Using Virus-Like Particles (OC02)

Dr Kathleen AERTGEERTS
Dr Kathleen AERTGEERTS
DART NEUROSCIENCE, San Diego, United States

Enabling Biophysics on Membrane Proteins Targets : Example of a Human Nucleoside Transporter (PL02)

Dr Nicolas BOCQUET
Dr Nicolas BOCQUET
LEADXPRO AG, Villigen, Switzerland
Read more

Biophysical Analysis to Aid and Complement Structure Based Drug Design for GPCRS (OC01)

Dr Carmen DREGGER
Dr Carmen DREGGER
HEPTARES THERAPEUTICS, Welwyn Garden City, United Kingdom

Use of Mini-G Proteins to Study the Activate State of G Protein-Coupled Receptors (PL01)

Dr Chris TATE
Dr Chris TATE
MRC LABORATORY OF MOLECULAR BIOLOGY, Cambridge, United Kingdom
Read more

Session 2: Recent Advances in NMR

Study of Protein Folding and Ligand Binding by Pressure Jump NMR (PL03)

Prof. Ad BAX
Prof. Ad BAX
NATIONAL INSTITUTES OF HEALTH, Bethesda, United States
Read more

New NMR Tools for Drug Discovery : From Validation to Structure Determination (PL04)

Dr Alvar GOSSERT
Dr Alvar GOSSERT
ETH ZÜRICH, Zürich, Switzerland
Read more

NMR as a Powerful Tool for Identifying Natural Compounds Able to Interfere with ELAV-mRNA Complexes (OC03)

Dr Francesca VASILE
Dr Francesca VASILE
UNIVERSITY OF MILANO, Milano, Italy

Session 3: Hot Topics

Precision of Biophysical Techniques that Determine Protein? Compound Dissociation Constants, Lessons from our Database of over 700 Ligand Kds Determined by ITC, FTSA(DSF), SPR, and SFA (OC05)

Prof. Daumantas MATULIS
Prof. Daumantas MATULIS
INSTITUTE OF BIOTECHNOLOGY, Vilnius, Lithuania

Biophysical Assays to Answer Evolving Questions in Drug Discovery (OC04)

Dr Derrick MEINHOLD
Dr Derrick MEINHOLD
GLAXOSMITHKLINE, Conshohocken, United States

Session 4: Recent Advances in FBDD

Fragment Screening against DC-SIGN Identifies Multiple Druggable Secondary Sites (OC07)

Mr Hannes BAUKMANN
Mr Hannes BAUKMANN
MAX PLANCK INSTITUTE OF COLLOIDS AND INTERFACES, Potsdam-Golm, Germany

A New Heuristic to Predict 3D Ligand Bound Conformation by Mining PDB Subpockets (OC08)

Mr Olivier BEQUIGNON
Mr Olivier BEQUIGNON
JANSSEN R&D, Val de Reuil Cedex, France

XCHEM: A High Throughput in Crystallo Fragment Screening Platform (OC06)

Dr Alexandre DIAS
Dr Alexandre DIAS
DIAMOND LIGHT SOURCE LTD, Didcot, Oxon, United Kingdom

Fragment Based Lead Generation – What Drives Success? (PL05)

Dr Jenny SANDMARK
Dr Jenny SANDMARK
ASTRAZENECA, Gothenburg, Sweden
Read more

Navigating Biophysical Space in Search of Medicines (PL06)

Dr Glyn WILLIAMS
Dr Glyn WILLIAMS
ASTEX PHARMACEUTICALS, Cambridge, United Kingdom
Read more

Session 5: Detecting Allosteric Effectors

Large Scale Protein Conformational Motions : From Fundamental Biophysics to Functional Dynamics (PL07)

Prof. Martin BLACKLEDGE
Prof. Martin BLACKLEDGE
IBS - INSTITUT DE BIOLOGIE STRUCTURALE, Grenoble, France
Read more

Analysis of Allosteric Modulators with Kinetic Fret (OC11)

Dr Martin REDHEAD
Dr Martin REDHEAD
UCB, Slough, United Kingdom

Surface Plasmon Resonance Based Method to Discriminate Direct Competition and Allosteric Effects in Ternary Systems (OC10)

Dr Armin RUF
Dr Armin RUF
F. HOFFMANN - LA ROCHE, Basel, Switzerland

Spectroscopic Adventures in Orthosteric and Allosteric Inhibition (PL08)

Dr Richard TAYLOR
Dr Richard TAYLOR
UCB, Slough, United Kingdom
Read more

Identifying Allosteric Modifiers of K-RAS Using Second Harmonic Generation (OC09)

Dr Elizabeth VO
Dr Elizabeth VO
UCSF, San Francisco, United States

Session 6: IDPs and the Dark Proteome

Finding Small-Molecules Inhibitors of the Interaction between the Intrinsically Disordered Androgen Receptor N-Terminal Domain and its Globular Partner RAP74 C-Terminal Domain (OC12)

Mrs Marta FRIGOLE-VIVAS
Mrs Marta FRIGOLE-VIVAS
INSTITUTE FOR RESEARCH IN BIOMEDICINE (IRB BARCELONA), Barcelona, Spain

Systematic Development of Small Molecules Against Aβ Aggregation (PL10)

Prof. Michele VENDRUSCOLO
Prof. Michele VENDRUSCOLO
UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom
Read more

Mechanistic Insights into TSPO and IDPs through NMR (PL09)

Prof. Markus ZWECKSTETTER
Prof. Markus ZWECKSTETTER
MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY, Göttingen, Germany
Read more

Session 7: Antibodies and Relatives

Adnectin Bioconjugates for PET Imaging and Targeted Drug Conjugates (PL11)

Dr Jim BRYSON
Dr Jim BRYSON
BRISTOL-MYERS-SQUIBB, Princeton, United States
Read more

Thermal Stabilization and Conformational Trapping of Membrane Transporters by in Vitro Selected Synthetic Nanobodies (PL12)

Prof. Markus SEEGER
Prof. Markus SEEGER
UNIVERSITY OF ZURICH, Zürich, Switzerland
Read more